Physician profile
Logan Debord
NPI 1104387794
$4,799.23
in general payments reported to CMS, 2019-2025
23 companies · $1,117 in 2025
The $1,117 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $917 · 2024: $2,765 · 2025: $1,117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,645 · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,644.98 |
| Education | $154.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $727.69 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $567.87 | 2024-2025 | Dupixent |
| Abbvie INC. | $526.65 | 2023-2024 | Rinvoq, Skyrizi |
| Dermavant Sciences, INC. | $403.52 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $361.13 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $358.25 | 2023-2025 | |
| Incyte Corporation | $314.24 | 2023-2025 | Opzelura |
| Ucb, INC. | $287.53 | 2023-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $278.45 | 2023-2025 | Taltz, Olumiant, Zepbound |
| Pfizer INC. | $239.90 | 2023-2025 | |
| Organon LLC | $149.19 | 2023-2025 | Vtama, Hadlima |
| E.R. Squibb & Sons, L.L.C. | $146.22 | 2023-2025 | Sotyktu |
| Leo Pharma INC. | $136.54 | 2023-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $54.22 | 2023-2024 | Tremfya, Simponi Aria, Simponi |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $43.65 | 2024 | Cabtreo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $40.54 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Arcutis Biotherapeutics, INC. | $33.17 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $28.71 | 2025 | Nemluvio |
| Krystal Biotech INC | $28.49 | 2025 | Vyjuvek |
| Solta Medical, A Division of Bausch Health US, LLC | $22.61 | 2024 | Clear+Brilliant |
| Verrica Pharmaceuticals INC. | $20.17 | 2024 | Ycanth |
| Amgen INC. | $16.16 | 2023 | Otezla |
| Journey Medical Corporation | $14.33 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Logan Debord listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.